Suppression of innate inflammation and immunity by interleukin-37

Charles A Dinarello, Claudia Nold-Petry, Marcel Nold, Mayumi Fujita, Suzhao Li, Soohyun Kim, Philip Bufler

Research output: Contribution to journalArticleResearchpeer-review

83 Citations (Scopus)

Abstract

IL-37 is unique in the IL-1 family in that unlike other members of the family, IL-37 broadly suppresses innate immunity. IL-37 can be elevated in humans with inflammatory and autoimmune diseases where it likely functions to limit inflammation. Transgenic mice expressing human IL-37 (IL37-tg) exhibit less severe inflammation in models of endotoxin shock, colitis, myocardial infarction, lung, and spinal cord injury. IL37-tg mice have reduced antigen-specific responses and dendritic cells (DCs) from these mice exhibit characteristics of tolerogenic DCs. Compared to aging wild-type (WT) mice, aging IL37-tg mice are protected against B-cell leukemogenesis and heart failure. Treatment of WT mice with recombinant human IL-37 has been shown to be protective in several models of inflammation and injury. IL-37 binds to the IL-18 receptor but then recruits the orphan IL-1R8 (formerly TIR8 or SIGIRR) in order to function as an inhibitor. Here, we review the discovery of IL-37, its production, release, and mechanisms by which IL-37 reduces inflammation and suppresses immune responses. The data reviewed here suggest a therapeutic potential for IL-37.

Original languageEnglish
Pages (from-to)1067-1081
Number of pages15
JournalEuropean Journal of Immunology
Volume46
Issue number5
DOIs
Publication statusPublished - 1 May 2016

Keywords

  • Autoinflammation
  • Caspase-1
  • IL-1 family
  • Toll receptors

Cite this

Dinarello, Charles A ; Nold-Petry, Claudia ; Nold, Marcel ; Fujita, Mayumi ; Li, Suzhao ; Kim, Soohyun ; Bufler, Philip. / Suppression of innate inflammation and immunity by interleukin-37. In: European Journal of Immunology. 2016 ; Vol. 46, No. 5. pp. 1067-1081.
@article{029bb3b581ab4bd8b4bdd72b6f40bb93,
title = "Suppression of innate inflammation and immunity by interleukin-37",
abstract = "IL-37 is unique in the IL-1 family in that unlike other members of the family, IL-37 broadly suppresses innate immunity. IL-37 can be elevated in humans with inflammatory and autoimmune diseases where it likely functions to limit inflammation. Transgenic mice expressing human IL-37 (IL37-tg) exhibit less severe inflammation in models of endotoxin shock, colitis, myocardial infarction, lung, and spinal cord injury. IL37-tg mice have reduced antigen-specific responses and dendritic cells (DCs) from these mice exhibit characteristics of tolerogenic DCs. Compared to aging wild-type (WT) mice, aging IL37-tg mice are protected against B-cell leukemogenesis and heart failure. Treatment of WT mice with recombinant human IL-37 has been shown to be protective in several models of inflammation and injury. IL-37 binds to the IL-18 receptor but then recruits the orphan IL-1R8 (formerly TIR8 or SIGIRR) in order to function as an inhibitor. Here, we review the discovery of IL-37, its production, release, and mechanisms by which IL-37 reduces inflammation and suppresses immune responses. The data reviewed here suggest a therapeutic potential for IL-37.",
keywords = "Autoinflammation, Caspase-1, IL-1 family, Toll receptors",
author = "Dinarello, {Charles A} and Claudia Nold-Petry and Marcel Nold and Mayumi Fujita and Suzhao Li and Soohyun Kim and Philip Bufler",
year = "2016",
month = "5",
day = "1",
doi = "10.1002/eji.201545828",
language = "English",
volume = "46",
pages = "1067--1081",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag GmbH & Co. KGaA",
number = "5",

}

Suppression of innate inflammation and immunity by interleukin-37. / Dinarello, Charles A; Nold-Petry, Claudia; Nold, Marcel; Fujita, Mayumi; Li, Suzhao; Kim, Soohyun; Bufler, Philip.

In: European Journal of Immunology, Vol. 46, No. 5, 01.05.2016, p. 1067-1081.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Suppression of innate inflammation and immunity by interleukin-37

AU - Dinarello, Charles A

AU - Nold-Petry, Claudia

AU - Nold, Marcel

AU - Fujita, Mayumi

AU - Li, Suzhao

AU - Kim, Soohyun

AU - Bufler, Philip

PY - 2016/5/1

Y1 - 2016/5/1

N2 - IL-37 is unique in the IL-1 family in that unlike other members of the family, IL-37 broadly suppresses innate immunity. IL-37 can be elevated in humans with inflammatory and autoimmune diseases where it likely functions to limit inflammation. Transgenic mice expressing human IL-37 (IL37-tg) exhibit less severe inflammation in models of endotoxin shock, colitis, myocardial infarction, lung, and spinal cord injury. IL37-tg mice have reduced antigen-specific responses and dendritic cells (DCs) from these mice exhibit characteristics of tolerogenic DCs. Compared to aging wild-type (WT) mice, aging IL37-tg mice are protected against B-cell leukemogenesis and heart failure. Treatment of WT mice with recombinant human IL-37 has been shown to be protective in several models of inflammation and injury. IL-37 binds to the IL-18 receptor but then recruits the orphan IL-1R8 (formerly TIR8 or SIGIRR) in order to function as an inhibitor. Here, we review the discovery of IL-37, its production, release, and mechanisms by which IL-37 reduces inflammation and suppresses immune responses. The data reviewed here suggest a therapeutic potential for IL-37.

AB - IL-37 is unique in the IL-1 family in that unlike other members of the family, IL-37 broadly suppresses innate immunity. IL-37 can be elevated in humans with inflammatory and autoimmune diseases where it likely functions to limit inflammation. Transgenic mice expressing human IL-37 (IL37-tg) exhibit less severe inflammation in models of endotoxin shock, colitis, myocardial infarction, lung, and spinal cord injury. IL37-tg mice have reduced antigen-specific responses and dendritic cells (DCs) from these mice exhibit characteristics of tolerogenic DCs. Compared to aging wild-type (WT) mice, aging IL37-tg mice are protected against B-cell leukemogenesis and heart failure. Treatment of WT mice with recombinant human IL-37 has been shown to be protective in several models of inflammation and injury. IL-37 binds to the IL-18 receptor but then recruits the orphan IL-1R8 (formerly TIR8 or SIGIRR) in order to function as an inhibitor. Here, we review the discovery of IL-37, its production, release, and mechanisms by which IL-37 reduces inflammation and suppresses immune responses. The data reviewed here suggest a therapeutic potential for IL-37.

KW - Autoinflammation

KW - Caspase-1

KW - IL-1 family

KW - Toll receptors

UR - http://www.scopus.com/inward/record.url?scp=84965025505&partnerID=8YFLogxK

U2 - 10.1002/eji.201545828

DO - 10.1002/eji.201545828

M3 - Article

VL - 46

SP - 1067

EP - 1081

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 5

ER -